



URL Pharma, Inc.
URL Distribution
Mutual Pharmaceutical Company, Inc.
AR Scientific, Inc.
1100 Orthodox Street
Philadelphia, PA 19124

Richard H. Roberts, M.D., Ph.D.
President
Chief Executive Officer

215-288-6500
www.urlpharma.com

November 30, 2010

Mr. James L. Martin
Chairman
60 Plus Association
515 King Street, Suite 315
Alexandria, VA 22314

Sent Via: Federal Express

RE: Correspondence dated November 15, 2010

Dear Mr. Martin:

Thank you for your letter of November 15, 2010. I appreciate the opportunity to respond to your question concerning the duration of our Colcrys® Patient Assistance Program (PAP) and to offer additional information about this initiative.

Most importantly, I want to assure you that we will continue to offer the PAP for the foreseeable future. In fact, we have committed to the FDA that the program will remain in force at least until the time that a generic product is made available.

We are committed to ensuring that patients who need Colcrys are able to access it, regardless of economic status. Under our program, patients who are uninsured or who have Medicare Part D coverage can receive Colcrys free of charge or at reduced cost. Uninsured and Medicare Part D patients with annual household incomes of up to three times the federal poverty level (for example, up to \$66,150 per year for a family of four) can receive Colcrys free of charge. Uninsured and Medicare Part D patients with household incomes between three to six times the federal poverty level (up to \$132,300 per year for a family of four) can receive Colcrys for \$5 or \$25 per month, depending upon income.

It is also important for seniors to know that the PAP has no impact on their Medicare Part D "donut hole." The only requirement is that patients will not claim co-payments on Medicare, Medicaid, other state and federal programs, or any private insurance.

Our program is comprehensive, and among the most generous ever offered in our industry, but we have chosen to take it a step further to ensure patient access. Any applications that may not qualify for the PAP cannot be rejected without first being reviewed by our corporate office. To date, every U.S citizen applicant has been granted assistance.

Page #2
November 30, 2010
Mr. James L. Martin


We have also undertaken a substantial educational effort to ensure that healthcare providers and patients are aware of the program and understand how to access it. Our efforts comprise a series of letters to physicians, pharmacists and health plans, e-mail alerts, direct mail communications and telephone outreach. Through these initiatives, we are providing over 2 million communications to healthcare providers and patients with information about the PAP. These efforts are in addition to the information about the program that is readily available to healthcare providers and patients on our website, www.colcrys.com, and other communications initiatives currently in the planning stage.

Our commitment to patients and healthcare providers is supported by a significant and ongoing financial investment. We have contracted with a non-profit organization to administer the PAP and donated product for this effort. URL Pharma receives no funds for any Colcrys prescription filled through the PAP. Additionally, to date we have invested about \$80 million researching colchicine and educating healthcare providers about our discoveries for the improved safety of their patients.

Thank you again for getting in touch with me. I hope that I have addressed your concerns and communicated some important points about Colcrys that patients should be aware of. We take our responsibility to patients very seriously and we are committed to helping the people who depend upon our medicines get the treatments that they need.

Please feel free to contact me if you have any other questions or concerns.

Sincerely,



Richard H. Roberts, M.D., Ph.D.
President & Chief Executive Officer

RHR/ph